Author:
Dacosta Byfield Stacey,Chen Diana,Yim Yeun Mi,Reyes Carolina
Abstract
AbstractThe epidemiology of non-melanoma skin cancer (NMSC) is not well understood due to exclusion from most US cancer registries. Patients with at least two claims with a NMSC diagnosis (ICD-9-CM 173.xx) at least 60 days apart, or at least one claim for a NMSC-specific treatment from 1/2010 to 12/2010, were identified from a large US commercial insurance claims database and grouped into one of three cohorts: metastatic (MET), locally advanced (LA), or “all other”. MET patients had at least two claims with a metastasis code at least 30 days apart. LA patients had at least two visits to a medical oncologist, one diagnostic imaging service, two radiation therapy services, or one visit to two or more physician specialties. Remaining patients were “all other”. Incidence and prevalence of NMSC were calculated from among the total number of persons continuously enrolled in the plan during the study period and standardized to the 2010 US population. From among 6,610,256 patients, there were 47,451 incident cases of NMSC (MET n = 16, LA n = 387, all other n = 47,048). The age-adjusted incidence rate of 693 per 100,000 persons (2010 population) approximates to 2,139,535 total NMSC cases in the US (0.7 % of population). 671 prevalent cases had advanced disease (MET n = 43, LA n = 628); an age-adjusted rate of 0.6 and 10 per 100,000 US persons equivalent to 1,993 and 29,841 MET and LA cases, respectively. Although NMSCs rarely progress, the number of patients with advanced disease is significant. Further studies to determine proportions of advanced NMSC by subtype are needed.
Publisher
Springer Science and Business Media LLC
Subject
Dermatology,General Medicine
Reference16 articles.
1. Athas WF, Hunt WC, Key CR (2003) Changes in nonmelanoma skin cancer incidence between 1977–1978 and 1998–1999 in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 12:1105–1108
2. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R (2007) Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 121:2105–2108. doi:10.1002/ijc.22952
3. Boi S, Cristofolini M, Micciolo R, Polla E, Dalla Palma P (2003) Epidemiology of skin tumors: data from the cutaneous cancer registry in Trentino, Italy. J Cutan Med Surg 7:300–305. doi:10.1007/s10227-002-0135-0
4. Centers for Medicare & Medicaid Services (2011) New, Revised, and Invalid Diagnosis and Procedure Codes FINAL VERSION – Effective January 10, 2011. http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/summarytables.html. Accessed 16 April 2013
5. Cherpelis BS, Marcusen C, Lang PG (2002) Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 28:268–273